FOLFOX联合贝伐单抗或西地尼布（AZD2171）作为转移性结直肠癌患者一线治疗的III期试验：HORIZON III
Phase III trial of FOLFOX plus bevacizumab or cediranib (AZD2171) as first-line treatment of patients with metastatic colorectal cancer: HORIZON III.
作者信息
Robertson Jane D, Botwood Nick A, Rothenberg Mace L, Schmoll Hans-Joachim
机构信息
AstraZeneca, Alderley Park, Macclesfield, UK.
出版信息
Clin Colorectal Cancer. 2009 Jan;8(1):59-60. doi: 10.3816/CCC.2009.n.010.
Cediranib is a highly potent and selective inhibitor of the 3 vascular endothelial growth factor receptors and has a halflife suitable for once-daily oral dosing. It is currently in phase III development for the first-line treatment of metastatic colorectal cancer. This article summarizes the clinical development program, which includes 2 global phase III studies, HORIZON II and HORIZON III, in the first-line treatment setting and a phase II study in second-line treatment (HORIZON I).
西地尼布是一种高效且具有选择性的3种血管内皮生长因子受体抑制剂，其半衰期适合每日一次口服给药。它目前正处于转移性结直肠癌一线治疗的III期开发阶段。本文总结了其临床开发项目，其中包括两项全球III期研究（HORIZON II和HORIZON III）用于一线治疗，以及一项II期研究用于二线治疗（HORIZON I）。
Zotero 插件